Medical Cannabis Innovator Set to Go Public

Initial Public Offering
  ()
A licensed producer of medical cannabis in Canada will begin trading on the Canadian Securities Exchange on Aug. 21. read more >

Maxim Raises Target Price of Biotech Company

Research Report
  ()
A year-over-year increase in sales of its flagship product, and the prospect that its technology could be used to promote the efficacy of cell therapies, helped spur a target price increase on this biotech. read more >

Immunotherapy Company's Q2 Revenue 'Handily Beats' H.C. Wainwright's Projection

Research Report
  ()
Analyst Ram Selvaraju with H.C. Wainwright & Co. provided an update on this biotech company's REVEAL clinical programs, as well as Q2/17 earnings that exceeded expectations. read more >

'Keep a Close Eye On' This Regenerative Medicine Firm

Research Report
  ()
In an update on this company's clinical cell therapy programs targeting blood cancers and osteoarthritis in the knee, Gabrielle Zhou of Maxim Group describes progress that sets the stage for "value inflection." read more >

Over-the-Counter Treatments for Joint Pain and Women's Health Propel Company into New Markets

  ()
With the launch of its over-the-counter combination treatment for joint pain and new licensing agreements for feminine lubrication product Zestra, this San Diego-based company is expanding both its therapeutic and international reach. read more >

Cell Therapy for Melanoma Impresses in
Phase 2

Research Report
  ()
Positive clinical data for this U.S. company's immunotherapy for metastatic melanoma are both encouraging and impressive, says one analyst. read more >

Company Developing Cannabinoid-Based Drug Therapy for Concussions Completes Reverse Takeover

Reverse Takeover
  ()
A drug developer working on a treatment for concussions expects to begin trading on the TSX Venture Exchange on Aug. 8. read more >
Expert Investing Ideas

"We continue to be optimistic about DRRX's story."

–Grant Zeng, Zacks Equity Research


Get Our Streetwise Reports Life Sciences Report Newsletter Free

A valid email address is required to subscribe
NASDAQ Biotech ARCA Pharmaceutical

This Just Changed Everything: Green Profits Are Being Unleashed

Contributed Opinion
  ()
Kenneth Ameduri, founder of Crush the Street, discusses why he believes now is a good time to take advantage of cannabis investing opportunities. read more >

Loan Provides Driver for Growth for Medical Device Firm

Research Report
  ()
Brian Marckx, analyst with Zacks Small-Cap Research, reports that a $20 million loan received by a U.S.-based medical device company could further fuel growth. read more >

Canadian Medical Cannabis Provider Expanding into US Market Through RTO

Reverse Takeover
  ()
A company with Canadian medical cannabis provider Aphria's backing is doing a reverse takeover on the Canadian Securities Exchange and expects to begin trading on July 26. read more >

Progress in Pain Control and Liver Disease Programs Spurs Rise in Company's Rating

Research Report
  ()
News about progress in two of this biotech's development programs prompted a rating upgrade by analyst Adam Walsh of Stifel Nicolaus & Company. read more >